Evidence map›Paper›PMID 40648805›Full record

ArticleJournal of clinical medicine2025

HALP-H Index as a Prognostic Biomarker for Predicting Pathological Complete Response in Early-Stage HER2-Positive Breast Cancer-A Multicenter Retrospective Cohort Study.

Mustafa Seyyar, Pervin Can Şancı, Tolga Köşeci, Anıl Karakayalı, Mutianur Özkorkmaz Akdağ, Yasemin Bakkal Temi, Kazım Uygun, Umut Kefeli, Burak Mete, Devrim Çabuk

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. PIV, PNI and HALP score for predicting pathological complete response in breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mustafa SeyyarDepartmant of Medical Oncology, Gaziantep City Hospital, Gaziantep 27100, Türkiye.
Pervin Can ŞancıDepartment of Medical Oncology, Kocaeli City Hospital, Kocaeli 41000, Türkiye.
Tolga KöşeciDepartment of Medical Oncology, Faculty of Medicine, Çukurova University, Adana 01250, Türkiye.
Anıl KarakayalıDepartment of Medical Oncology, Kocaeli City Hospital, Kocaeli 41000, Türkiye.
Mutianur Özkorkmaz AkdağDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, Türkiye.
Yasemin Bakkal TemiDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, Türkiye.ORCID 0000-0002-1268-6666
Kazım UygunDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, Türkiye.
Umut KefeliDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, Türkiye.ORCID 0000-0001-6126-5377
Burak MeteDepartment of Public Health, Faculty of Medicine, Çukurova University, Adana 01250, Türkiye.
Devrim ÇabukDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HALP-H indexHER2-positive breast cancerneoadjuvant treatmentpathological response

Identifiers

PMID40648805
PMCPMC12250440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.